Single dose of psychedelic nasal spray reduced treatment-resistant depression symptoms for eight weeks

A clinical trial published in JAMA reveals that a single dose of a fast-acting psychedelic nasal spray may offer rapid relief for individuals with treatment-resistant depression. The study, conducted by researchers at the Kadima Neuropsychiatry Institute in La Jolla, California, and King's College London, found that patients treated with the spray experienced a significant reduction in depressive symptoms within eight weeks.

Treatment-resistant depression, affecting approximately one-third of those with major depressive disorder, is characterized by persistent symptoms that do not improve with standard antidepressant treatments. Existing therapies for this condition, such as esketamine nasal spray or magnetic brain stimulation, often require frequent clinic visits and may carry side effects.

Psychedelic drugs, which act on serotonin receptors in the brain, have shown promise in reducing depressive symptoms, but traditional forms require lengthy in-clinic supervision. Mebufotenin, the active ingredient in the nasal spray, is a synthetic compound that activates serotonin receptors rapidly and is eliminated quickly from the body, resulting in a brief psychedelic experience.

In the trial, participants aged 18 to 75 with treatment-resistant depression received either 8 milligrams, 12 milligrams, or a low-effective 0.3-milligram dose of the spray. Improvements in depression severity were evident as early as day 2, with both higher doses showing significant reductions in symptoms compared to the control group.

The study's findings suggest that short-acting psychedelics like the nasal spray may provide a practical and effective alternative to traditional treatments for individuals with treatment-resistant depression.